A daily dose of transdermal testosterone for 16 weeks improved sexual satisfaction.
A daily 90-µL dose of transdermal testosterone for 16 weeks modestly increased the mean number of satisfactory sexual events (SSEs)-by almost one per month-among premenopausal women with a reduced libido and a low serum-free testosterone level at baseline.
The somewhat ambiguous results come from a randomized, double-blind, placebo-controlled trial involving six Australian medical centers and 261 women aged 35 to 46 years who reported a decrease in satisfying sexual activity and who had a morning serum-free testosterone level less than 3.8 pmol/L (<1.1 pg/mL).
One smaller and one larger dose of transdermal testosterone were also tested that yielded results similar to that found with placebo, indicating an absence of a dose-response relationship. In fact, the number of SSEs increased in all four groups, including in the placebo group.
Basson R. Testosterone supplementation to improve women's sexual satisfaction: complexities and unknowns. Ann Intern Med. 2008;148:620-621.
Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. 2008;148:569-577.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More